SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. Financials Shenzhen Kangtai Biological Products Co., Ltd.
Equities
300601
CNE100002Q33
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.2 CNY | -0.83% |
|
-2.65% | -25.60% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 56,644 | 119,407 | 67,700 | 27,232 | 30,324 | 22,562 | - | - |
| Enterprise Value (EV) 1 | 56,644 | 119,407 | 66,889 | 28,504 | 31,593 | 23,659 | 23,445 | 22,896 |
| P/E ratio | 97.5 x | 173 x | 54.1 x | -263 x | 35.3 x | 16.6 x | 12.6 x | 9.85 x |
| Yield | - | - | 0.86% | - | 0.74% | 0.84% | 2.49% | 1.29% |
| Capitalization / Revenue | 29.1 x | 52.8 x | 18.5 x | 8.62 x | 8.72 x | 4.97 x | 3.94 x | 3.59 x |
| EV / Revenue | 29.1 x | 52.8 x | 18.3 x | 9.03 x | 9.09 x | 5.21 x | 4.09 x | 3.64 x |
| EV / EBITDA | 76.3 x | 135 x | 35.5 x | -322 x | 26.6 x | 17 x | 10.7 x | 10.5 x |
| EV / FCF | 475 x | - | -75.3 x | -37.3 x | 100 x | 66.3 x | 22 x | 12.9 x |
| FCF Yield | 0.21% | - | -1.33% | -2.68% | 1% | 1.51% | 4.54% | 7.76% |
| Price to Book | 20.6 x | 16 x | 7.82 x | 4.17 x | 3.36 x | 2.02 x | 1.73 x | - |
| Nbr of stocks (in thousands) | 1,032,353 | 1,094,851 | 1,099,252 | 863,699 | 1,116,912 | 1,116,917 | - | - |
| Reference price 2 | 54.87 | 109.1 | 61.59 | 31.53 | 27.15 | 20.20 | 20.20 | 20.20 |
| Announcement Date | 2/28/20 | 4/29/21 | 4/13/22 | 4/23/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,943 | 2,261 | 3,652 | 3,157 | 3,477 | 4,544 | 5,725 | 6,287 |
| EBITDA 1 | 742.1 | 881.9 | 1,885 | -88.53 | 1,190 | 1,389 | 2,186 | 2,177 |
| EBIT 1 | 657.8 | 775.4 | 1,452 | -317.6 | 948.9 | 1,318 | 1,961 | 2,050 |
| Operating Margin | 33.85% | 34.29% | 39.76% | -10.06% | 27.29% | 29% | 34.26% | 32.61% |
| Earnings before Tax (EBT) 1 | 663.4 | 772.4 | 1,439 | -338.2 | 940.3 | 1,316 | 1,991 | 2,077 |
| Net income 1 | 574.5 | 679.2 | 1,263 | -132.7 | 861.3 | 1,158 | 1,694 | 1,848 |
| Net margin | 29.56% | 30.04% | 34.59% | -4.2% | 24.77% | 25.48% | 29.58% | 29.39% |
| EPS 2 | 0.5625 | 0.6312 | 1.138 | -0.1200 | 0.7700 | 1.218 | 1.600 | 2.050 |
| Free Cash Flow 1 | 119.3 | - | -888 | -764.6 | 315.6 | 357 | 1,065 | 1,776 |
| FCF margin | 6.14% | - | -24.31% | -24.22% | 9.08% | 7.86% | 18.6% | 28.25% |
| FCF Conversion (EBITDA) | 16.08% | - | - | - | 26.53% | 25.7% | 48.72% | 81.57% |
| FCF Conversion (Net income) | 20.77% | - | - | - | 36.64% | 30.83% | 62.88% | 96.11% |
| Dividend per Share 2 | - | - | 0.5312 | - | 0.2000 | 0.1700 | 0.5025 | 0.2600 |
| Announcement Date | 2/28/20 | 4/29/21 | 4/13/22 | 4/23/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,275 | 871.4 | 956.4 | 737.2 | 592.3 | 748.4 | 982.2 | 733.9 | 1,013 | 451.7 | 1,013 | 1,224 | 1,380 | 989.9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 255.8 | 327.2 | -239 | 64.69 | -470.2 | 244.3 | 322 | 202.4 | 180.2 | 69.94 | 329.1 | 305.1 | 344 | 266.5 |
| Operating Margin | 20.07% | 37.55% | -24.98% | 8.77% | -79.37% | 32.65% | 32.78% | 27.58% | 17.79% | 15.49% | 32.48% | 24.93% | 24.93% | 26.93% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | -153.1 | 82.64 | -335.9 | - | 305 | 186.6 | - | - | - | - | - | - |
| Net margin | - | - | -16.01% | 11.21% | -56.7% | - | 31.05% | 25.43% | - | - | - | - | - | - |
| EPS | 0.2062 | - | -0.2236 | 0.0693 | -0.3600 | - | 0.2763 | 0.1600 | - | - | - | - | - | - |
| Dividend per Share | 0.0531 | - | - | - | - | - | 0.1800 | - | - | - | - | - | - | - |
| Announcement Date | 4/13/22 | 4/27/22 | 8/18/22 | 10/27/22 | 4/23/23 | 4/23/23 | 8/26/23 | 10/26/23 | 4/26/24 | 4/26/24 | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 1,272 | 1,269 | 1,098 | 883 | 335 |
| Net Cash position 1 | - | - | 811 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -14.37 x | 1.067 x | 0.7902 x | 0.404 x | 0.1537 x |
| Free Cash Flow 1 | 119 | - | -888 | -765 | 316 | 357 | 1,065 | 1,776 |
| ROE (net income / shareholders' equity) | 25.5% | 12.6% | 15.1% | -1.44% | 9.26% | 13.2% | 13.4% | 17.7% |
| ROA (Net income/ Total Assets) | 15.8% | - | 9.04% | - | - | 9% | 8.58% | 11.9% |
| Assets 1 | 3,644 | - | 13,970 | - | - | 12,865 | 19,751 | 15,528 |
| Book Value Per Share 2 | 2.670 | 6.810 | 7.870 | 7.560 | 8.090 | 9.980 | 11.70 | - |
| Cash Flow per Share 2 | 0.4900 | 0.4000 | 1.500 | 0.4900 | 0.9300 | 0.7600 | 1.160 | - |
| Capex 1 | 386 | 1,226 | 2,540 | 1,310 | 717 | 853 | 708 | 715 |
| Capex / Sales | 19.88% | 54.2% | 69.56% | 41.5% | 20.63% | 18.78% | 12.37% | 11.37% |
| Announcement Date | 2/28/20 | 4/29/21 | 4/13/22 | 4/23/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
20.2
CNY
Average target price
35.68
CNY
Spread / Average Target
+76.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.60% | 3.12B | |
| -3.79% | 88.14B | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B |
- Stock Market
- Equities
- 300601 Stock
- Financials Shenzhen Kangtai Biological Products Co., Ltd.
